Wall Street slips from its records as JPMorgan Chase and Delta kick off earnings season

U.S. equities slipped from record highs as the S&P 500 fell 0.4% and the Dow dropped 344 points amid a mixed start to the Q4 2025 earnings season; FactSet expects S&P 500 EPS to be up 8.3% year‑over‑year. JPMorgan reported weaker-than-expected profit and revenue, Delta missed revenue and midpoint guidance, while healthcare names outperformed (Moderna +16.3% after raising 2025 revenue guidance; Revvity +5.1% with profit above prior range). The CPI reading showed headline inflation at +2.7% YoY—slightly above forecasts but with a softer underlying trend—pushing the 10‑year Treasury to ~4.16% and the 2‑year to ~3.52% and keeping markets focused on the possibility of multiple Fed rate cuts in 2026; L3Harris plans to spin off Missile Solutions via an IPO with a $1bn U.S. government investment converting to common stock.

Analysis

Market structure: The modest broad-market pullback (S&P -0.4%) amid mixed earnings signals re-prices growth vs safety: healthcare/biotech (MRNA, RVTY) are beneficiaries from upside guidance while rate-sensitive sectors and banks (JPM, DAL, CMG) face two-way pressure as markets price ~2 Fed cuts in 2026. Bond yields (10y 4.16%, 2y 3.52%) underpin a rotation into duration if CPI momentum softens; conversely a re-acceleration in core inflation would re-favor financials. Expect increased dispersion: top-quartile EPS beats will drive single-name leadership rather than broad index gains over next 1–3 months.

Risk assessment: Tail risks include a breakdown of Fed independence that re-prices long-term inflation expectations (10y +100bp shock) and a sequencing risk where active buybacks/one-off charges (JPM Apple Card) mask real earnings weakness. Near-term (days-weeks) earnings noise can trigger ±5–10% swings in individual names; medium-term (quarters) macro pivots (if CPI >3% persist) would shift capital into cyclicals and commodities. Hidden dependency: health-care upside hinges on FDA timelines for Moderna’s flu vaccine and FY26 product cadence — binary catalysts within 6–12 months.

Trade implications: Favor selective long healthcare/biotech momentum (MRNA, RVTY) sized 1–3% with option-defined risk and rotate out of high-expectation consumer names (CMG) and airlines (DAL) where guidance missed midpoints. Use bond-duration as a tactical hedge: add 2–4% duration exposure if 10y breaches ≤4.10% or if CPI 3-month annualized falls below 2.5%. Maintain small tactical long on LHX (1–2%) for defense restructuring optionality ahead of the Missile Solutions IPO.

Contrarian angles: Consensus of two 2026 cuts may be underpriced for inflation re-acceleration risks — short-duration complacency is a mispricing if core inflation stabilizes >2.5%. The JPM selloff likely overstates franchise risk from a one-off balance-sheet acquisition impact; consider buying on >7% pullback. Finally, healthcare rallies may be under-owned; if MRNA revenue revisions continue above midpoint, patient accumulation ahead of regulatory readouts could outperform for 3–12 months.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long position in MRNA via 3–6 month call spreads (debit) to cap downside; enter within 10 trading days and trim if post-earnings guidance reverses or shares drop >12% from entry.
• Initiate a 1%–2% long position in RVTY (or equivalent long-biotech basket) and size options exposure so maximum loss ≤1% portfolio; target hold 3–9 months to capture post-guidance re-rating.
• Trim 15%–25% of exposure to CMG and DAL over the next 2–4 weeks; redeploy proceeds into healthcare longs and add 1–2% to LHX for a 6–12 month hold, exit if IPO terms dilute LHX ownership by >15% or government backing is rescinded.
• Tactically increase duration by 2–4% (e.g., IEF/TLT) conditioned on 10-year Treasuries sliding to ≤4.10% or if CPI 3-month annualized falls below 2.5%; conversely reduce duration and hedge equities if 10y rises >50bp from current levels.